Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.89 USD | +1.63% | +6.78% | -6.44% |
Apr. 22 | European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations | MT |
Apr. 16 | QIAGEN NV : Deutsche Bank reiterates its Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 23.24 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.69 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.44% | 9.12B | A | ||
+3.13% | 42.11B | B | ||
+48.83% | 40.08B | A | ||
+8.49% | 40B | B- | ||
-10.82% | 26.87B | C | ||
+8.26% | 24.58B | B- | ||
-23.69% | 18.44B | B | ||
+1.58% | 11.94B | C+ | ||
+32.83% | 11.66B | C+ | ||
+6.63% | 11.01B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QGEN Stock
- Ratings Qiagen N.V.